-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Cadrenal Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2022 to Q2 2025.
- Cadrenal Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2025 was -$3.73M, a 51.4% decline year-over-year.
- Cadrenal Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2025 was -$14.4M, a 117% decline year-over-year.
- Cadrenal Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$11M, a 43.6% decline from 2023.
- Cadrenal Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$7.63M, a 183% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)